Targets of emerging therapies for viral hepatitis B and C

Expert Opinion on Therapeutic Targets

Volumn 10, Issue 6, 2006, Pages 833-850

  Yerly, Daniel ^a,c   Di Giammarino, Loriana ^b   Bihl, Florian ^c   Cerny, Andreas ^a,d  

^a UNIVERSITY OF BERN   (Switzerland)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d Ospedale Regionale di Lugano   (Switzerland)

Author keywords

Gene therapy; Hepatitis B virus; Hepatitis C virus; Immune therapy; Nucleoside analogue; Nucleotide analogue; Polymerase inhibitor; Protease inhibitor; Therapeutic vaccine

Indexed keywords

A 848837; ADEFOVIR; AMANTADINE; ANTIVIRUS AGENT; CILUPREVIR; CLEVUDINE; EMTRICITABINE; ENTECAVIR; HCV 796; HEPATITIS B VACCINE; HEPATITIS C VACCINE; INOSINATE DEHYDROGENASE; ITMN 191; LAMIVUDINE; MK 0608; NM 283; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PROTEINASE; PROTEINASE INHIBITOR; R 1626; RIBAMIDINE; RIBAVIRIN; RNA DIRECTED RNA POLYMERASE; SCH 503034; TELBIVUDINE; TENOFOVIR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALOPICITABINE; VX 950; XTL 2125;

ANTIVIRAL ACTIVITY; CARDIOTOXICITY; CLINICAL TRIAL; DIARRHEA; DISEASE COURSE; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENTIATION; DRUG SAFETY; DRUG TARGETING; DRUG TREATMENT FAILURE; ENZYME INHIBITION; GASTROINTESTINAL TOXICITY; GENE EXPRESSION REGULATION; GENETIC CODE; HEMOLYTIC ANEMIA; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INFECTION RISK; MAXIMUM PERMISSIBLE DOSE; MONOTHERAPY; NAUSEA; NONHUMAN; NONVIRAL GENE THERAPY; PRACTICE GUIDELINE; REVIEW; RISK ASSESSMENT; RISK FACTOR; RNA INTERFERENCE; TUBULAR DYSFUNCTION; VERTICAL TRANSMISSION; VIRAL GENE DELIVERY SYSTEM; VIRUS LOAD; VIRUS REPLICATION; VIRUS RESISTANCE; VIRUS TRANSMISSION; VOMITING;

ANTIVIRAL AGENTS; HEPATITIS B; HEPATITIS C; HUMANS; SUBSTRATE SPECIFICITY;

EID: 33751438066     PISSN: 14728222     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728222.10.6.833     Document Type: Review

References (145)

1. EGGER D, WOLK B, GOSERT R et al.: Expression of hepatitis C virus proteins induces distinct membrane alterations including a candidate viral replication complex. J. Virol. (2002) 76(12):5974-5984.
2. MACDONALD A, HARRIS M: Hepatitis C virus NS5A: tales of a promiscuous protein. J. Gen. Virol. (2004) 85(Pt 9):2485-2502.
3. PENIN F, DUBUISSON J, REY FA, MORADPOUR D, PAWLOTSKY JM: Structural biology of hepatitis C virus. Hepatology (2004) 39(1):5-19.
4. LINDENBACH BD, EVANS MJ, SYDER AJ et al.: Complete replication of hepatitis C virus in cell culture. Science (2005) 309(5734):623-626.
5. WAKITA T, PIETSCHMANN T, KATO T et al.: Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat. Med. (2005) 11(7):791-796.
6. ZHONG J, GASTAMINZA P, CHENG G et al.: Robust hepatitis C virus infection in vitro. Proc. Natl. Acad. Sci. USA (2005) 102(26):9294-9299.
7. BAIN C, FATMI A, ZOULIM F et al.: Impaired allostimulatory function of dendritic cells in chronic hepatitis C infection. Gastroenterology (2001) 120(2):512-524.
8. SUNG VM, SHIMODAIRA S, DOUGHTY AL et al.: Establishment of B-cell lymphoma cell lines persistently infected with hepatitis C virus in vivo and in vitro: the apoptoric effects of virus infection. J. Virol. (2003) 77(3):2134-2146.
9. HOOFNAGLE JH: Course and outcome of hepatitis C. Hepatology (2002) 36(5 Suppl. 1):S21-S29.
10. GREMION C, CERNY A: Hepatitis C virus and the immune system: a concise review. Rev. Med. Virol. (2005) 15(4):235-268.
11. LANG L: NIH consensus development conference updates HCV management. Gastroenterology (2002) 123(2):404.
12. DEGOS F, CHRISTIDIS C, GANNE-CARRIE N et al.: Hepatitis C virus related cirrhosis: time to occurrence of hepatocellular carcinoma and death. Gut (2000) 47(1):131-136.
13. FATIFOVICH G, GIUSTINA G, SCHALM SW et al.: Occurrence of hepatocellular carcinoma and decompensation in western European patients with cirrhosis type B. The EUROHEP study group on hepatitis B virus and cirrhosis. Hepatology (1995) 21(1):77-82.
14. CHEN SL, MORGAN TR: The natural history of hepatitis C virus (HCV) infection. Int. J. Med. Sci. (2006) 3(2):47-52.
15. STRADER DB, WRIGHT T, THOMAS DL, SEEFF LB: Diagnosis, management, and treatment of hepatitis C. Hepatology (2004) 39(4):1147-1171.
16. FRIED MW, SHIFFMAN ML, REDDY KR et al.: Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N. Engl. J. Med. (2002) 347(13):975-982.
17. MANNS MR MCHUTCHISON JG, GORDON SC et al.: Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet (2001) 358(9286):958-965.
18. HADZIYANNIS SJ, SETTE H, JR., MORGAN TR et al.: Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann. Intern. Med. (2004) 140(5):346-355.
19. DIENSTAG JL, MCHUTCHISON JG: American Gastroenterological Association medical position statement on the management of hepatitis C. Gastroenterology (2006) 130(1):225-230.
20. BLINDENBACHER A, DUONG FH, HUNZIKER L et al.: Expression of hepatitis c virus proteins inhibits interferon alpha signaling in the liver of transgenic mice. Gastroenterology (2003) 124(5):1465-1475.
21. LAU JY, TAM RC, LLANG TJ, HONG Z: Mechanism of action of ribavirin in the combination treatment of chronic HCV infection. Hepatology (2002) 35(5):1002-1009.
22. NAOUMOV NV: Immunomodulatory properties of interferon alpha and ribavirin. 41st Meeting of the European Association for the Study of Liver Diseases. 26 - 30 April, Vienna, Austria (2006).
23. LIN CC, PHILIPS L, XU C, YEH LT: Pharmacokinetics and safety of viramidine, a prodrug of ribavirin, in healthy volunteers. J. Clin. Pharmacol. (2004) 44(3):265-275.
24. BENHAMOU Y, POCKROS P, RODRIQUEZ-TORRES M et al.: The safety and efficacy of viramidine plus pegIFN alfa-2b versus ribavirin plus pegIFN alfa-2b in therapy naïve patients with HCV: Phase III results (VISER1). 41st Meeting of the European Association for the Study of Liver Diseases. 26 - 30 April, Vienna, Austria (2006).
25. LAYDEN TJ, LAYDEN JE, REDDY KR et al.: Induction therapy with consensus interferon (CIFN) does not improve sustained virologic response in chronic hepatitis C. J. Viral Hepat. (2002) 9(5):334-339.
26. BOCHER WO, SCHUCHMANN M, LINK R et al.: Consensus interferon and ribavirin for patients with chronic hepatitis C and failure of previous interferon-alpha therapy. Liver Int. (2006) 26(3):319-325.
27. ZEUZEM S, BENHAMOU Y, SHOUVAL D et al.: Interim (Week 12) Phase IIB virological efficacy and safety results of albuferon (albumin interferon alfa-2b) combined with ribavirin in genotype 1 treatment-naive chronic hepatitis C infection. 41th Meeting of the European Association for the Study of Liver. 26 - 30 April, Vienna, Austria (2006).
28. LI XD, SUN L, SETH RB, PINEDA G, CHEN ZJ: Hepatitis C virus protease NS3/ 4A cleaves mitochondrial antiviral signaling protein off the mitochondria to evade innate immunity. Proc. Natl. Acad. Sci. USA (2005) 102(49):17717-17722.
29. FOY E, LI K, SUMPTER R Jr et al.: Control of antiviral defenses through hepatitis C virus disruption of retinoic acid-inducible gene-I signaling. Proc. Natl. Acad. Sci. USA (2005) 102(8):2986-2991.
30. FOY E, LI K, WANG C et al.: Regulation of interferon regulatory factor-3 by the hepatitis C virus serine protease. Science (2003) 300(5622):1145-1148.
31. HINRICHSEN H, BENHAMOU Y, WEDEMEYER H et al.: Short-term antiviral efficacy of BILN 2061, a hepatitis C virus serine protease inhibitor, in hepatitis C genotype 1 patients. Gastroenterology (2004) 127(5):1347-1355.
32. LAMARRE D, ANDERSON PC, BAILEY M et al.: An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus. Nature (2003) 426(6963):186-189.
33. REISER M, HINRICHSEN H, BENHAMOU Y et al.: Antiviral efficacy of NS3-serine protease inhibitor BILN-2061 in patients with chronic genotype 2 and 3 hepatitis C. Hepatology (2005) 41(4):832-835.
34. PERNI RB, ALMQUIST SJ, BYRN RA et al.: Preclinical profile of VX-950, a potent, selective, and orally bioavailable inhibitor of hepatitis C virus NS3-4A serine protease. Antimicrob. Agents Chemother. (2006) 50(3):899-909.
35. LAWITZ E, RODRIGUEZ-TORRES M, MUIR A et al.: 28 days of hepatitis c protease inhibitor VX-950, in combination with Peg-interferon-alfa-2a and ribavirin, is well-tolerated and demonstrates robust antiviral effects. Digestive Disease Week. 20 - 25 April, Los Angeles, California, USA (2006).
36. REESINK H: Final results of a Phase Ib, multiple-dose study of VX-950, a hepatitis C virus protease inhibitor. 56th Annual Meeting of the American Association for the Study of Liver Diseases. 11 - 15 November, San Francisco, CA, USA (2005).
37. +/- ribavirin non-responders: antiviral activity & HCV variant analysis. 41st Meeting of the European Association for the Study of Liver Diseases. 26 - 30 April, Vienna, Austria (2006).
38. RIEGER RA, LEE PAL, SEIWERT S et al.: Pharmacokinetic analysis and liver concentrations of a series of macrocyclic peptidomimetic inhibitors of HCV NS3/4A protease: identification of ITMN-191, a potent NS3/4A protease inhibitor with high liver exposure across multiple species. Digestive Diseases Week. 21 - 24 May, Los Angeles, CA, USA (2005).
39. LIN C, GATES CA, RAO BG et al.: In vitro studies of cross-resistance mutations against two hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061. J. Biol. Chem. (2005) 280(44):36784-36791.
40. BISWAL BK, CHERNEY MM, WANG M et al.: Crystal structures of the RNA-dependent RNA polymerase genotype 2a of hepatitis C virus reveal two conformations and suggest mechanisms of inhibition by non-nucleoside inhibitors. J. Biol. Chem. (2005) 280(18):18202-18210.
41. POCKROS P, O'BRIEN C, GODOFSKY E et al.: NM283 + Peg: differences in response between treatment naives & nonresponders; dose reductions for safety concerns Digestive Disease Week. 21 - 24 May, Los Angeles, CA, USA (2006)
42. ROBERTS S, COOKSLEY G, SHAW D et al.: Interim results of a multiple ascending dose study of R1626, a novel nucleoside analog targeting HCV polymerase in chronic HCV patients. 41st Annual Meeting of the European Association. 26 - 30 April, Vienna, Austria (2006).
43. OLSEN D: Robust suppression of viral replication in HCV INFECTED by nucleoside inhibitor MK-0608. l5th International HIV Drug Resitance Workshop. 13 - 17 June, Sitges, Spain (2006).
44. VILLANO S: Antiviral Activity of the Non-Nucleoside Polymerase Inhibitor, HCV-796, in patients with chronic HCV: preliminary results from a randomized, double-blind, placebo-controlled, ascending multiple dose study. Digestive Disease Week. May 21 - 24, Los Angeles, CA, USA (2006)
45. MOLLA A. Selection and charaterization of mutations conferring resistance to a HCV RNA dependant RNA polymerase inhibitor A-848837 in vitro. l5th International HIV Drug Resistance Workshop. 13 - 17 June, Sitges, Spain (2006)
46. SUMMA V, PETROCCHI A, PACE P et al.: Discovery of alphagamma-diketo acids as potent selective and reversible inhibitors of hepatitis C virus NS5b RNA-dependent RNA polymerase. J. Med. Chem. (2004) 47(1):14-17.
47. KOCH U, ATTENNI B, MALANCONA S et al.: 2-(2-Thienyl)-5,6-dihydroxy4-carboxypyrimidines as inhibitors of the hepatitis C virus NS5B polymerase: discovery, SAR, modeling and mutagenesis. J. Med. Chem. (2006) 49(5):1693-1705.
48. MAGA G, GEMMA S, FATTORUSSO C et al.: Specific targeting of hepatitis C virus NS3 RNA helicase. Discovery of the potent and selective competitive nucleotide-mimicking inhibitor QU663. Biochemistry (2005) 44(28):9637-9644.
49. BOROWSKI P, DEINERT J, SCHALINSKI S et al.: Halogenated benzimidazoles and benzotriazoles as inhibitors of the NTPase/helicase activities of hepatitis C and related viruses. Eur. J. Biochem. (2003) 270(8):1645-1653.
50. GRIFFIN SD, BEALES LP, CLARKE DS et al.: The p7 protein of hepatitis C virus forms an ion channel that is blocked by the antiviral drug, Amantadine. FEBS Lett. (2003) 535(1-3):34-38.
51. PAVLOVIC D, NEVILLE DC, ARGAUD O et al.: The hepatitis C virus p7 protein forms an ion channel that is inhibited by long-alkyl-chain iminosugar derivatives. Proc. Natl. Acad. Sci. USA (2003) 100(10):6104-6108.
52. HWANG DR, LIN RK, LEU GZ et al.: Inhibition of hepatitis C virus replication by antimonial compounds. Antimicrob. Agents Chemother. (2005) 49(10):4197-4202.
53. YEH CT, HWANG DR, LAI HY, HSU JT: Inhibition of authentic hepatitis C virus replication by sodium stibogluconate. Biochem. Biophys. Res. Commun. (2003) 310(2):537-541.
54. PAESHUYSE J, COELMONT L, VLIEGEN I et al.: Hemin potentiates the anti-hepatitis C virus activity of the antimalarial drug artemisinin. Biochem. Biophys. Res. Commun. (2006) 348(1):139-144.
55. MA S, BOERNER JE, TIONGYIP C et al.: NIM811, a cyclophilin inhibitor, exhibits potent in vitro activity against hepatitis C virus alone or in combination with alpha interferon. Antimicrob. Agents Chemother. (2006) 50(9):2976-2982.
56. PAESHUYSE J, KAUL A, DE CLERCQ E et al.: The non-immunosuppressive cyclosporin DEBIO-025 is a potent inhibitor of hepatitis C virus replication in vitro. Hepatology (2006) 43(4):761-770.
57. ZHANG H, HANECAK R, BROWN-DRIVER V et al.: Antisense oligonucleotide inhibition of hepatitis C virus (HCV) gene expression in livers of mice infected with an HCV-vaccinia virus recombinant. Antimicrob. Agents Chemother. (1999) 43(2):347-353.
58. HANECAK R, BROWN-DRIVER V, FOX MC et al.: Antisense oligonucleotide inhibition of hepatitis C virus gene expression in transformed hepatocytes. J. Virol. (1996) 70(8):5203-5212.
59. MCHUTCHISON JG, PATEL K, POCKROS P et al.: A Phase I trial of an antisense inhibitor of hepatitis C virus (ISIS 14803), administered to chronic hepatitis C patients. J. Hepatol. (2006) 44(1):88-96.
60. IVERSEN P, AMANTANA A, STEIN D et al.: AVI-4065, an antisense approach to active HCV infection; preclinical and clinical evaluation. 19th International Conference on Antiviral Research. 7 - 11 May, San Juan, Puerto Rico (2006).
61. RYU KJ, KIM JH, LEE SW: Ribozyme-mediated selective induction of new gene activity in hepatitis C virus internal ribosome entry site-expressing cells by targeted trans-splicing. Mol. Ther. (2003) 7(3):386-395.
62. RYU KJ, LEE SW: Comparative analysis of intracellular trans-splicing ribozyme activity against hepatitis C virus internal ribosome entry site. J. Microbiol. (2004) 42(4):361-364.
63. TONG M, SCHIFF E, JACOBSON I, EVERSEN G, MCHUTCHISON JG: Preliminary analysis of a Phase II study of Heptazyme™, a nuclease resistant ribozyme targeting hepatitis C (HCV) RNA. Hepatology (2002) 36:360A
64. HANNON GJ: RNA interference. Nature (2002) 418(6894):244-251.
65. WILSON JA, RICHARDSON CD: Hepatitis C virus replicons escape RNA interference induced by a short interfering RNA directed against the NS5b coding region. J. Virol. (2005) 79(11):7050-7058.
66. KRONKE J, KITTLER R, BUCHHOLZ F et al.: Alternative approaches for efficient inhibition of hepatitis C virus RNA replication by small interfering RNAs. J. Virol. (2004) 78(7):3436-3446.
67. YOKOTA T, SAKAMOTO N, ENOMOTO N et al.: Inhibition of intracellular hepatitis C virus replication by synthetic and vector-derived small interfering RNAs. EMBO Rep. (2003) 4(6):602-608.
68. WANG Q, CONTAG CH, ILVES H, JOHNSTON BH, KASPAR RL: Small hairpin RNAs efficiently inhibit hepatitis C IRES-mediated gene expression in human tissue culture cells and a mouse model. Mol. Ther. (2005) 12(3):562-568.
69. + T-helper-cell responses in resolved hepatitis C virus infection. J. Virol. (2002) 76(24):12584-12595.
70. + T lymphocytes in acute and chronic hepatitis C. J. Mol. Med. (1996) 74(10):583-588.
71. CHEN M, SALLBERG M, SONNERBORG A et al.: Limited humoral immunity in hepatitis C virus infection. Gastroenterology (1999) 116(1):135-143.
72. BARTOSCH B, DUBUISSON J, COSSET FL: Infectious hepatitis C virus pseudo-particles containing functional E1-E2 envelope protein complexes. J. Exp. Med. (2003) 197(5):633-642.
73. YU MY, BARTOSCH B, ZHANG P et al.: Neutralizing antibodies to hepatitis C virus (HCV) in immune globulins derived from anti-HCV-positive plasma. Proc. Natl. Acad. Sci. USA (2004) 101(20):7705-7710.
74. EREN R, LANDSTEIN D, TERKIELTAUB D et al.: Preclinical evaluation of two neutralizing human monoclonal antibodies against hepatitis C virus (HCV): a potential treatment to prevent HCV reinfection in liver transplant patients. J. Virol. (2006) 80(6):2654-2664.
75. LAI ME, MAZZOLENI AP, ARGIOLU F et al.: Hepatitis C virus in multiple episodes of acute hepatitis in polytransfused thalassaemic children. Lancet (1994) 343(8894):388-390.
76. MURATA K, LECHMANN M, QIAO M et al.: Immunization with hepatitis C virus-like particles protects mice from recombinant hepatitis C virus-vaccinia infection. Proc. Natl. Acad. Sci. USA (2003) 100(11):6753-6758.
77. JEONG SH, QIAO M, NASCIMBENI M et al.: Immunization with hepatitis C virus-like particles induces humoral and cellular immune responses in nonhuman primates. J. Virol. (2004) 78(13):6995-7003.
78. FIRBAS C, JILMA B, TAUBER E et al.: Immunogenicity and safety of a novel therapeutic hepatitis C virus (HCV) peptide vaccine: A randomized, placebo controlled trial for dose optimization in 128 healthy subjects. Vaccine (2006) 24(20):4343-4353.
79. KLADE CS, FIRBAS C, BÜRGER V et al.: Optimization of schedule, route and adjuvant of therapeutic peptide vaccines against HCV. In: Intercell 2006.
80. LEROUX-ROELS G, DEPLA E, HULSTAERT F et al.: A candidate vaccine based on the hepatitis C E1 protein: tolerability and immunogenicity in healthy volunteers. Vaccine (2004) 22(23-24):3080-3086.
81. MCHUTCHISON G, BACON BR, GORDON SC et al.: Randomized, placebo-controlled, dose-escalation trial of new HCV drug CPG 10101 toll-receptor antagonist in patients with chronic hepatitis C virus. 41st Meeting of the European Association for the Study of Liver Diseases. 26 - 30 April, Vienna, Austria (2006).
82. HORSMANS Y, BERG T, DESAGER JP et al.: Isatoribine, an agonist of TLR7, reduces plasma virus concentration in chronic hepatitis C infection. Hepatology (2005) 42(3):724-731.
83. ISOGAWA M, ROBEK MD, FURUICHI Y, CHISARI FV: Toll-like receptor signaling inhibits hepatitis B virus replication in vivo. J. Virol. (2005) 79(11):7269-7272.
84. NORDER H, COUROUCE AM, COURSAGET P et al.: Genetic diversity of hepatitis B virus strains derived worldwide: genotypes, subgenotypes, and HBsAg subtypes. Intervirology (2004) 47(6):289-309.
85. BARTHOLOMEUSZ A, SCHAEFER S: Hepatitis B virus genotypes: comparison of genotyping methods. Rev. Med. Virol. (2004) 14(1):3-16.
86. KOCK J, THEILMANN L, GALLE P, SCHLICHT HJ: Hepatitis B virus nucleic acids associated with human peripheral blood mononuclear cells do not originate from replicating virus. Hepatology (1996) 23(3):405-413.
87. MURAKAMI Y, MINAMI M, DAIMON Y, OKANOUE T: Hepatitis B virus DNA in liver, serum, and peripheral blood mononuclcar cells after the clearance of serum hepatitis B virus surface antigen. J. Med. Virol. (2004) 72(2):203-214.
88. UMEDA M, MARUSAWA H, SENO H et al.: Hepatitis B virus infection in lymphatic tissues in inactive hepatitis B carriers. J. Hepatol. (2005) 42(6):806-812.
89. REHERMANN B, NASCIMBENI M: Immunology of hepatitis B virus and hepatitis C virus infection. Nat. Rev. Immunol. (2005) 5(3):215-229.
90. WEINBERGER KM, BAUER T, BOHM S, JILG W: High genetic variability of the group-specific a-determinant of hepatitis B virus surface antigen (HBsAg) and the corresponding fragment of the viral polymerase in chronic virus carriers lacking detectable HBsAg in serum. J. Gen. Virol. (2000) 81(Pt 5):1165-1174.
91. BIHL F, CASTELLI D, MARINCOLA F, BRANDER C: The often disregarded, yet present risk of transfusion-transmitted diseases. Lancet (2006) (In Press).
92. BERTOLETTI A, GEHRING AJ: The immune response during hepatitis B virus infection. J. Gen. Virol. (2006) 87(Pt 6):1439-1449.
93. LOK AS, MCMAHON BJ: Chronic hepatitis B. Hepatolgy (2001) 34(6):1225-1241.
94. HADZIYANNIS SJ, VASSILOPOULOS D: Hepatitis B e antigen-negative chronic hepatitis B. Hepatology (2001) 34(4 Pt 1):617-624.
95. LOK AS: Prevention of hepatitis B virus-related hepatocellular carcinoma. Gastroenterology (2004) 127(5 Suppl. 1):S303-S309.
96. LOK AS, HEATHCOTE EJ, HOOFNAGLE JH: Management of hepatitis B:2000-summary of a workshop. Gastroenterology (2001) 120(7):1828-1853.
97. LAU GK, PIRATVISUTH T, LUO KX et al.: Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N. Engl. J. Med. (2005) 352(26):2682-2695.
98. CRAXI A, ANTONUCCI G, CAMMA C: Treatment options in HBV. J. Hepatol. (2006) 44(1 Suppl.):S77-S83.
99. MANESIS EK, HADZIYANNIS SJ: Interferon alpha treatment and retreatment of hepatitis B e antigen-negative chronic hepatitis B. Gastroenterology (2001) 121(1):101-109.
100. BRUNETTO MR, OLIVERI F, COCO B et al.: Outcome of anti-HBe positive chronic hepatitis B in alpha-interferon treated and untreated patients: a long term cohort study. J. Hepatol. (2002) 36(2):263-270.
101. MARCELLIN P, LAU GK, BONINO F et al.: Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N. Engl. J. Med. (2004) 351(12):1206-1217.
102. JANSSEN HL, VAN ZONNEVELD M, SENTURK H et al.: Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet (2005) 365(9454):123-129.
103. GANEM D, PRINCE AM: Hepatitis B virus infection-natural history and clinical consequences. N. Engl. J. Med. (2004) 350(11):1118-1129.
104. YUEN MF, TANAKA Y, LAI CL: Hepatitis B genotypes in chronic hepatitis B and lamivudine therapy. Intervirology (2003) 46(6):373-376.
105. QUAN DJ, PETERS MG: Antiviral therapy: nucleotide and nucleoside analogs. Clin. Liver Dis. (2004) 8(2):371-385.
106. SEVERINI A, LIU XY, WILSON JS, TYRRELL DL: Mechanism of inhibition of duck hepatitis B virus polymerase by (-)-beta-L-2′,3′-dideoxy-3′-thiacytidine. Antimicrob. Agents Chemother. (1995) 39(7):1430-1435.
107. DIENSTAG JL, SCHIFF ER, WRIGHT TL et al.: Lamivudine as initial treatment for chronic hepatitis B in the United States. N. Engl. J. Med. (1999) 341(17):1256-1263.
108. LIAW YF, LEUNG NW, CHANG TT et al.: Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. Gastroenterology (2000) 119(1):172-180.
109. PERRILLO RP, LAI CL, LIAW YF et al.: Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B. Hepatology (2002) 36(1):186-194.
110. DIENSTAG JL: The value and limitations of long-term nucleoside antiviral therapy in chronic hepatitis B. J. Hepatol. (2005) 42(2):158-162.
111. DIENSTAG JL, GOLDIN RD, HEATHCOTE EJ et al.: Histological outcome during long-term lamivudine therapy. Gastroenterology (2003) 124(1):105-117.
112. LIM SG, NG TM, KUNG N et al.: A double-blind placebo-controlled study of emtricitabine in chronic hepatitis B. Arch. Intern. Med. (2006) 166(1):49-56.
113. GISH RG, TRINH H, LEUNG N et al.: Safety and antiviral activity of emtricitabine (FTC) for the treatment of chronic hepatitis B infection: a two-year study. J. Hepatol. (2005) 43(1):60-66.
114. BRYANT ML, BRIDGES EG, PLACIDI L et al. Anti-HBV specific beta-L-2′-deoxynucleosides. Nucleosides Nucleotides Nucleic Acids (2001) 20(4-7):597-607.
115. LE GUERHIER F, PICHOUD C, JAMARD C et al.: Antiviral activity of beta-L-2′,3′-dideoxy-2′,3′-didehydro-5-fluo rocytidine in woodchucks chronically infected with woodchuck hepatitis virus. Antimicrob. Agents Chemother. (2001) 45(4):1065-1077.
116. SEMIZAROV DG, ARZUMANOV AA, DYATKINA NB et al.: Stereoisomers of deoxynucleoside 5′-triphosphates as substrates for template-dependent and -independent DNA polymerases. J. Biol. Chem. (1997) 272(14):9556-9560.
117. LAI CL, LEUNG N, TEO EK et al.: A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B. Gastroenterology (2005) 129(2):528-536.
118. LAI CL, GANE E, LIAW YF et al.: Telbivudine (LDT) versus larnivudine for chronic hepatitis B: first-year results from the international Phase III GLOBE trial. 56th Annual Meeting of the American Association for the Study of Liver Diseases. 14 November, San Fransisco, CA, USA (2005).
119. LAI CL BN, MYERS M et al.: Valtorcitabina provides potent suppression of hepatitis B virus in patients with chronic hepatitis B: results of a Phase I/II clinical trial. J. Hepatol. (2004) 40(Suppl. 1):173A.
120. TENNANT BC, BALDWIN BH, GRAHAM LA et al.: Antiviral activity and toxicity of fialuridine in the woodchuck model of hepatitis B virus infection. Hepatology (1998) 28(1):179-191.
121. KORBA BE, COTE P, HORNBUCKLE W, TENNANT BC, GERIN JL: Treatment of chronic woodchuck hepatitis virus infection in the Eastern woodchuck (Marmota monax) with nucleoside analogues is predictive of therapy for chronic hepatitis B virus infection in humans. Hepatology (2000) 31(5):1165-1175.
122. MARCELLIN P, MOMMEJA-MARIN H, SACKS SL et al.: A Phase II dose-escalating trial of clevudine in patients with chronic hepatitis B. Hepatology (2004) 40(1):140-148.
123. LEE HS, CHUNG YH, LEE K et al.: A 12-week clevudine therapy showed potent and durable antiviral activity in hbeag-positive chronic hepatitis B. Hepatology (2006) 43(5):982-988.
124. ZHOU Y YT, CULLEN J, SAPUTELLI J et al.: Kinetics of hepadnavirus loss from the liver during inhibition of viral DNA synthesis. J. Virol. (2001) 75:311-322.
125. MARCELLIN P, CHANG TT, LIM SG et al.: Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N. Engl. J. Med. (2003) 348(9):808-816.
126. HADZIYANNIS SJ, TASSOPOULOS NC, HEATHCOTE EJ et al.: Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N. Engl. J. Med. (2003) 348(9):800-807.
127. ANGUS P, VAUGHAN R, XIONG S et al.: Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase. Gastroenterology (2003) 125(2):292-297.
128. HADZIYANNIS SJ, TASSOPOULOS NC, HEATHCOTE EJ et al.: Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B. N. Engl. J. Med. (2005) 352(26):2673-2681.
129. SCHILDGEN O, SIRMA H, FUNK A et al.: Variant of hepatitis B virus with primary resistance to adefovir. N. Engl. J. Med. (2006) 354(17):1807-1812.
130. PETERS MG, HANN HW H, MARTIN P et al.: Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology (2004) 126(1):91-101.
131. LAU D AO: Safety, tolerability, pharmacokinetics and pharmacodynamics of remofovir in chronic HBV patients in USA and Canada following daily dosing for 28 days. 40th Meeting of the European Association for the Study of Liver Diseases. 13 - 17 May, Paris, France (2005).
132. CHERRINGTON JM, ALLEN SJ, MCKEE BH, CHEN MS: Kinetic analysis of the interaction between the diphosphate of (S)-1-(3-hydroxy-2-phosphonylmethoxyp ropyl)cytosine, ddCTP, AZTTP, and FIAUTP with human DNA polymerases beta and gamma. Biochem. Pharmacol. (1994) 48(10):1986-1988.
133. WILSON JE, MARTIN JL, BORROTO-ESODA K et al.: The 5′-triphosphates of the (-) and (+) enantiomers of cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolane-5-yl] cytosine equally inhibit human immunodeficiency virus Type 1 reverse transcriptase. Antimicrob. Agents Chemother. (1993) 37(8):1720-1722.
134. BENHAMOU Y, POYNARD T: Treatment of chronic hepatitis B virus infection in patients co-infected with human immunodeficiency virus. J. Hepatol. (2003) 39(Suppl. 1):S194-S199.
135. PETERS M. Tenofovir and emtricitabine in the monotherapy for hepatitis B In: Abstract and program of the management of Hepatitis B Virus National Institutes of Health Workshop. Bethesda, Maryland, USA (2006).
136. VAN BOMMEL F, WUNSCHE T, MAUSS S et al.: Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection. Hepatology (2004) 40(6):1421-1425.
137. QI X SA, THIBAULT V, ZHU Y, CURTIS M, HADZIYANNIS S et al.: Week 144 resistance surveillance of adefovir dipivoxil-treated chronic hepatitis B patients Digestive Disease Week. 15 - 20 May, New Orleans, LA, USA (2004).
138. SEIFER M, HAMATAKE RK, COLONNO RJ, STANDRING DN: In vitro inhibition of hepadnavirus polymerases by the triphosphates of BMS-200475 and lobucavir. Antimicrob. Agents Chemother. (1998) 42(12):3200-3208.
139. LAI CL, SHOUVAL D, LOK AS et al.: Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N. Engl. J. Med. (2006) 354(10):1011-1020.
140. CHANG TT, GISH RG, DE MAN R et al.: A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N. Engl. J. Med. (2006) 354(10):1001-1010.
141. LEVINE S, HERNANDEZ D, YAMANAKA G et al.: Efficacies of entecavir against lamivudine-resistant hepatitis B virus replication and recombinant polymerases in vitro. Antimicrob. Agents Chemother. (2002) 46(8):2525-2532.
142. TENNEY DJ, LEVINE SM, ROSE RE et al.: Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to lamivudine. Antimicrob. Agents Chemother. (2004) 48(9):3498-3507.
143. MCCAFFREY AP, NAKAI H, PANDEY K et al.: Inhibition of hepatitis B virus in mice by RNA interference. Nat. Biotechnol. (2003) 21(6):639-644.
144. MORRISSEY DV, LOCKRIDGE JA, SHAW L et al.: Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs. Nat. Biotechnol. (2005) 23(8):1002-1007.
145. SCHALM SW, HEATHCOTE J, CIANCIARA J et al.: Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial. Gut (2000) 46(4):562-568.